STEVENSON, Md., April 25, 2014 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of purchasers of Galena Biopharma, Inc. ("Galena" or the "Company") (GALE) common stock during the period between May 9, 2013 and March 17, 2014, inclusive (the "Class Period").

If you have suffered a net loss from investment in Galena common stock purchased on or after May 9, 2013 and held through the revelation of negative information during and/or at the end of the Class Period, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or financial obligation, click here: www.browerpiven.com/securitiesfraudcases.html.

You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616. Attorneys at Brower Piven together have more than a century of experience litigating securities and other class action cases.

No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than May 5, 2014 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company units during the Class Period.

The Complaint alleges that throughout the Class Period defendants misrepresented and/or failed to disclose that: (1) the Company hired a promoter, The DreamTeam Group, to boost Galena's share price; (2) the promoter posted misleading articles on Galena's behalf without properly disclosing its paid marketing relationship; and (3) as a result, the Company's statements were materially false and misleading at all relevant times.

If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

I can do this all day....

Don't insult my intelligence

for starters pre market high was $2.47...THAT is a fact!

"since the news" the HOD reached $2.42...THAT is a fact!

"since the HOD of $2.42" it is now trading for $2.25...THAT is a fact!

Being down approximately 2% on the day (which isn't even over) is NOT a "significant" drop"...however, since the low of April 15th low of $1.66 GALE has gained significantly...THAT is a fact!

What else you got?

NEW YORK, April 23, 2014 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Oregon on behalf of holders of Galena Biopharma, Inc. ("Galena" or the "Company") (GALE) securities between November 6, 2013 and February 14, 2014.

For more information, click here: zlk.9nl.com/galenabiopharma-gale.

The complaint alleges that throughout the Class Period, Galena made false and/or misleading statements that led to the artificial inflation of Galena's stock price, allowing its Chief Executive Officer to sell $3.8 million worth of his Galena stock.

On February 12, 2014, an article featured on TheStreet.com alleged Galena was engaging in a misleading campaign aimed at boosting its stock price, alleging that investor relations firm The DreamTeam Group had published articles under aliases promoting the Company's stock without disclosing their sponsorship. Then on February 14, 2014, Galena acknowledged that it had paid the investor relations firm The DreamTeam Group to promote the Company.

If you suffered a loss in Galena you have until May 5, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/galenabiopharma-gale.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

NEW YORK, April 22, 2014 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. today reminds all purchasers of the common stock of Galena Biopharma, Inc. (GALE) between November 6, 2013 and February 14, 2014, inclusive of the important May 5, 2014 lead plaintiff deadline in the class action filed by the firm.

To join the Galena class action, go to the website at rosenlegal.com or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, Defendants made false and/or misleading statements and/or failed to disclose that Galena was engaged in a misleading stock promotion. When this adverse information entered the market, the price of Galena stock fell, damaging investors. As a result, the SEC is now investigating Galena.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2014. If you wish to join the litigation or to discuss your rights or interests regarding this class action, please contact, Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm focuses on prosecuting securities class action litigation and actions involving financial fraud. The Rosen Law Firm represents investors throughout the globe concentrating its practice in securities class actions.

BENSALEM, Pa.--(BUSINESS WIRE)--

Law Offices of Howard G. Smith announces that the class action lawsuit against Galena Biopharma, Inc. (“Galena” or the “Company”) (GALE) filed in the United States District Court for the District of Oregon has been expanded to include all purchasers of Galena common stock between May 9, 2013 and March 17, 2014, inclusive (the “Class Period”).

Galena is a biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. The Complaint alleges that throughout the Class Period defendants misrepresented and/or failed to disclose that: (1) the Company hired a promoter – The DreamTeam Group – to boost Galena’s share price; (2) the promoter posted misleading articles on Galena’s behalf without properly disclosing its paid marketing relationship; and (3) as a result, the Company’s statements were materially false and misleading at all relevant times.

If you purchased Galena shares during the Class Period, you may move the Court no later than May 5, 2014, to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

Boston, MA 04/21/2014 (wallstreetpr) – Galena Biopharma Inc (NASDAQ:GALE) is a publicly operated pharmaceutical company in the U.S. with its primary focus on cancer therapy. The company is currently facing an investigation from the US Securities and Exchange Commission. It has been charged with the allegations of using false and unlawful methods for creating hype and effectively raising its share price value in the market.

Payments made to PR firm

SEC is investigating the role of an investor relations firm in Galena’s rise of stock prices. It is claimed that the company was secretly paying an outside PR firm an amount to promote it. The firm being called ‘Dream Team’ was writing positive articles and giving feedbacks praising and promoting the company. The articles were written under aliases .This led to an increasing popularity among the people and thus created a demand for its shares. The stock price of Galena showed a significant increase in its share value from $2 to $4. The company leveraged the opportunity and made a huge profit by selling its thousands of shares and making million dollars profits. Hagens Berman Sobol Shapiro LLP, a law firm for investor’s law class is currently investigating the charges against Galena.

Galena denies charges

The company is facing five law cases although it continues to reject all the allegations of creating a buzz for demand of its share. Four of these five cases fall under the jurisdiction of Federal Court for violating the shareholder protection law. The last day for filing lead plaintiff is May 5, 2014 in the securities fraud class action. Earlier the company had claimed of huge advancements that are now overcast by the investigations. The company has also incurred a loss of $48.5 million in the last quarter of 2013. On a single share, the company suffered a loss of $0.46.

Persons with information about Galena can have an advantage from SEC Whistle blower program. Under the program, the person who claims to provide non-public original information can get up to 30% of recovered amount by SEC.

SAN FRANCISCO, April 16, 2014 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP an investor-rights law firm with offices in San Francisco has intensified its investigation on behalf of Galena Biopharma, Inc. (GALE) ("Galena" or "the Company") in light of the May 5, 2014 deadline to file for lead plaintiff in the securities fraud cases against the company. Investors who purchased Galena stock between May 9, 2013 and March 17, 2014 (the "Class Period") can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000, emailing Galena@hbsslaw.com or visiting hb-securities.com/investigations/Galena.





The complaints, which were filed in the U.S. District Court for the District of Oregon, will likely be consolidated into one class action upon appointment of the lead plaintiff, and generally allege that unbeknownst to investors, Galena hired The DreamTeam Group and Mission IR, two affiliated promotional agents, to inflate the value of Galena common stock during the Class Period. The 240-day endeavor, which ended in March 2014, was anchored by a campaign of planting fraudulent analyst reports and news articles that touted the company, its product pipeline and a drug marketed and manufactured by the company, Abstral, according to the complaints.

The complaints state that in many instances, these fraudulent media reports were written under aliases. In all instances, the authors never disclosed that they were paid by DreamTeam to write these media reports or that Galena executives had complete editorial control over their work, the complaints state. The publication of these fraudulent media reports coincided with positive company announcements, such as successful clinical trials and the launch of Abstral, so as to have maximum impact upon Galena's share price, complaints state.

Galena's officers and directors sold nearly $10 million worth of Galena stock during the period when Galena's stock price was artificially inflated, the complaints allege.

On March 17, 2014 Galena revealed that the company learned in February of an SEC investigation involving "certain matters related to our company and an outside investor-relations firm that we retained in 2013." Galena's shares dropped more than nine percent in after-hours trading following the company's announcement of the SEC investigation. Galena stock continues to trade below previous figures, closing at $1.74 on April 15, 2014.

"If true, defendant's hiring of The DreamTeam Group to promote the company through a front of undisclosed writers seriously undermines the credibility of management," said Mr. Kathrein. "Even worse, it appears to have been a clear attempt to inflate Galena's stock price in a classic 'pump and dump' manner."

The deadline to file for lead plaintiff in the securities fraud class action is May 5, 2014.

Persons with non-public information regarding Galena should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC Whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email one of the links above.

Very very worst case is 2.30 for Gale

1.65 to say themleast, no way it (GALE) would go down below these levels even with current legal issues

Summary
•For all the positive results from NeuVax clinical studies, the ethical shortcomings of Galena's management mean that the future of the company is uncertain.

Galena's two-sided future
Galena released its 2013 results Monday, March 17. Everything was going hunky-dory until the part that talks about the company being investigated by the SEC. To be honest, the results were quite impressive and they, to some extent, give assurance that the company is headed in the right direction.

In fact, that Abstral's sales came in within the company's forecast of $1.5 to $3 million gives hope that the new forecast of $11 million to $15 million is achievable. However, the ongoing SEC investigation is a big dent on the image of the management at Galena.

I don't expect this to affect the approval of NeuVax -- as long as it genuinely helps cancer patients. And considering the positive signals so far, I think the drug is genuinely helpful. Therefore, without being emotional, the long-term case for this company looks positive.

However, since emotions can't be taken out of a discussion that involves the hopes of cancer patients, we need to take a second look. Truth be told, regardless of how promising the drug is, it's so unethical and heartless of anyone to want to profit at the expense of dying cancer patients.

It gives a feeling that the execs at Galena are there, first, to make profits before thinking of helping the world. If it had never happened, we would hardly think of it ever happening. But now that it has happened, there is every chance that something as callous as this could happen in future. In fact, no one can say for sure that the company can't tamper with clinical results.

Therefore, in reality, the long-term future of the company hinges on hopes that the management would learn from this, and change for the better - which is uncertain. In view of this, investors might be better off without positions in this company.

SAN FRANCISCO--(BUSINESS WIRE)--


Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the May 5, 2014 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of those who purchased or otherwise acquired the securities of Galena Biopharma, Inc. (“Galena” or the “Company”) (GALE) between May 9, 2013 and March 17, 2014, inclusive (the “Class Period”).

If you purchased or otherwise acquired the securities of Galena during the Class Period, you may move the Court for appointment as lead plaintiff by no later than May 5, 2014. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

Galena investors who wish to learn more about the action and how to seek appointment as lead plaintiff should click here or contact Sharon M. Lee of Lieff Cabraser toll-free at 1-800-541-7358.

The actions charge Galena and certain of its officers and directors with violations of the federal securities laws. The actions allege that, throughout the Class Period, defendants failed to disclose that Galena had hired a promoter to boost its share price and that the promoter had posted misleading articles on behalf of Galena without properly disclosing its paid relationship.

On February 12, 2014, TheStreet.com published an article claiming that Galena had paid an investor relations firm, The DreamTeamGroup (“The DreamTeam”), to publish articles under aliases promoting Galena’s stock without disclosing who had paid for them. On this news, the price of Galena’s stock fell $0.85 per share, or 16.38%, to close at $4.34 per share on February 12, 2014.

On February 14, 2014, Galena issued a letter to shareholders conceding that it had hired The DreamTeam. On this news, the price of Galena’s stock fell an additional $0.63 per share, or 14.4%, to close at $3.73 per share.

On March 17, 2014, Galena announced that it was under investigation by the Securities and Exchange Commission. On this news, the price of Galena’s stock dropped $0.40 per share, or 12.42%, to close at $2.82 on March 18, 2014.

Pomerantz LLP
1 hour ago




NEW YORK, April 11, 2014 /PRNewswire/ -- Pomerantz LLP has filed a class action lawsuit against Galena Biopharma, Inc. ("Galena" or the "Company")(GALE) and certain of its officers. The class action, filed in United States District Court, District of Oregon, and docketed under 3:14-cv-00410-HZ, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Galena securities between March 12, 2013 and February 11, 2014, both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Galena securities during the Class Period, you have until May 5, 2014 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

Galena Biopharma, Inc. is a biopharmaceutical company that focuses on developing oncology treatments to address major unmet medical needs to advance cancer care.

The Complaint alleges that throughout the Class Period, Defendants orchestrated a scheme to increase the value of the Company's publicly traded stock so that insiders could reap the benefits by selling millions of dollars of shares of the Company's stock. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Galena paid $50,000 to a subsidiary of The DreamTeam Group ("DreamTeam") for 240 days of "advertising, branding, marketing, investor relations and social media services"; (ii) certain of DreamTeam's marketing tactics resembled stock promotion schemes which ran afoul of standard investor relations practices; (iii) DreamTeam published favorable articles about Galena on Seeking Alpha that failed to disclose that they were published by DreamTeam and instead appeared to be written from the perspective of individual investors recommending an investment in Galena; (iv) insiders took advantage of the resulting run up in the Company's stock to sell millions of dollars of shares at artificially inflated prices, coinciding with DreamTeam's promotional efforts; (v) this type of stock promotion coupled with heavy insider selling would ultimately cause massive losses to investors as the public became aware of the "pump and dump" scheme; and (vi) as a result of the foregoing, the Company's financial statements were materially false and misleading at all relevant times.

On February 12, 2014, a report was published by a TheStreet.com stating that Galena "Pays For Stock-Touting Campaign While Insiders Cash Out Millions", describing the Company's stock promotion scheme. On this news, Galena Biopharma shares declined $0.85, or over 16%, to close at $4.34 per share on February 12, 2014.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.